| Yang, Yang |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT05250843: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC |
|
|
| Recruiting | 2/3 | 90 | RoW | TACE/HAIC, Lenvatinib, Sintilimab, liver resection | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma | 12/23 | 12/24 | | |
NCT06272214: Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy |
|
|
| Recruiting | 2 | 146 | RoW | Adjuvant radiotherapy, Observation | Zhejiang Cancer Hospital | Adjuvant Radiotherapy | 03/27 | 03/29 | | |
NCT06413342: Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 191 | RoW | Sintilimab | Zhejiang Cancer Hospital | Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy, Elderly Patients | 06/26 | 06/28 | | |
IIT-2024-238, NCT06509568: Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） |
|
|
| Recruiting | 2 | 92 | RoW | Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy | Zhejiang Cancer Hospital | Esophageal Squamous Cell Carcinoma | 08/25 | 08/26 | | |
NCT05738057: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Camrelizumab, Gemcitabine Injection, Cisplatin injection, Cisplatin-Eluting Beads, D-TACE | Hua Li | Unresectable Intrahepatic Cholangiocarcinoma | 03/25 | 03/26 | | |
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 80 | US, RoW | HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule | Shanghai Huaota Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 08/25 | 08/25 | | |
NCT05940610: The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure |
|
|
| Withdrawn | 1/2 | 20 | RoW | MSC-EVs | Third Affiliated Hospital, Sun Yat-Sen University | Acute-On-Chronic Liver Failure, Acute Liver Failure | 09/24 | 10/25 | | |
NCT05881668: MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation |
|
|
| Withdrawn | 1 | 30 | RoW | MSC-EV | Third Affiliated Hospital, Sun Yat-Sen University | Liver Failure, Acute on Chronic | 09/24 | 04/25 | | |
Neo-DRATEC, NCT03381651: Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma |
|
|
| Completed | N/A | 147 | RoW | Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation | Zhejiang Cancer Hospital | Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery | 02/21 | 02/23 | | |
| Recruiting | N/A | 300 | US | T'ai Chi and Qigong Rehabilitation, Usual care | New York Presbyterian Hospital, Center for Taiji and Qigong Studies & Wa-Qi.com | Low Back Pain | 06/23 | 06/23 | | |
NCT04707053: Data Collection and Analysis in Brainstem Surgeries |
|
|
| Recruiting | N/A | 150 | Europe | | Cantonal Hospital of St. Gallen | Brainstem Lesion, Surgery, Intraoperative Neurophysiologic Monitoring | 12/23 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | internet plus model, control | Guizhou Provincial People's Hospital | Neonatal Jaundice | 10/24 | 05/25 | | |
UTTS, NCT06743477: A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme |
|
|
| Not yet recruiting | N/A | 5 | RoW | Supergraft | Hu Peng | Stem Cell Transplantation | 12/26 | 12/26 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Lai, Wei |
NCT06565884: Study on the Safety, Efficacy of Home RF Cosmetic Instrument in the Treatment of Facial or Periorbital Wrinkles（F-MFR300-RD-003） |
|
|
| Completed | N/A | 224 | RoW | Home radiofrequency skin treatment instrument, Ultrasonic coupler for medical purposes | Flossom (GD) Beauty Technology Co., Ltd. | Skin Wrinkles | 09/23 | 09/23 | | |
YM-1, NCT06441799: Study on the Safety, Efficacy of Home RF Cosmetic Instrument in the Treatment of Facial or Periorbital Wrinkles |
|
|
| Completed | N/A | 224 | RoW | Home radiofrequency skin treatment instrument, Ultrasonic coupler for medical purposes | Glomed(HN)Co.Ltd | Skin Wrinkles | 08/23 | 08/23 | | |
| Recruiting | N/A | 300 | RoW | Rocuronium priming dose | Taipei Medical University Hospital | Neuromuscular Blockade | 12/24 | 12/24 | | |
| Li, Hua |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT05250843: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC |
|
|
| Recruiting | 2/3 | 90 | RoW | TACE/HAIC, Lenvatinib, Sintilimab, liver resection | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma | 12/23 | 12/24 | | |
NCT05565573: Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients |
|
|
| Recruiting | 2/3 | 148 | RoW | Medroxyprogesterone Acetate 500 MG Oral Tablet, MPA, Levonorgestrel-Releasing Intrauterine System, LNG-IUS, 52-mg LNG-IUS，Mirena | Hua Li | Fertility Sparing | 07/24 | 11/25 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT04492787: Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) |
|
|
| Completed | 2 | 240 | NA | Changkang Granule, Changkang Placebo Granule | Tasly Pharmaceutical Group Co., Ltd | Irritable Bowel Syndrome with Diarrhea | 04/22 | 04/22 | | |
NCT04839926: A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects |
|
|
| Recruiting | 1 | 60 | RoW | 0.5mg CY150112, placebo, 1.5mg CY150112, 4.5mg CY150112, 10mg CY150112, 18mg CY150112, 24mg CY150112 | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Schizophrenia | 08/21 | 08/21 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
NCT03936504: Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation Model |
|
|
| Recruiting | N/A | 100 | RoW | Control Group ：conventional exercise rehabilitation programs (CERP), Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP) | Chinese PLA General Hospital, Beijing Normal University | Coronary Heart Disease, Chronic Coronary Syndrome | 07/21 | 10/21 | | |
NCT06232213: Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC Model |
|
|
| Recruiting | N/A | 40 | RoW | | Hua Li | Personalized Cancer Treatment | 09/26 | 09/26 | | |
| Completed | N/A | 52 | US | Halcyon 4.0 system | Washington University School of Medicine, Varian Medical Systems | Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer | 10/24 | 10/24 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
AIM, NCT05032053: Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds |
|
|
| Recruiting | N/A | 3000 | RoW | Antithrombotic drugs | Xijing Hospital, Ankang Central Hospital, Yan'an University Affiliated Hospital | Ischemic Stroke | 12/25 | 10/26 | | |
| Recruiting | N/A | 60 | US | Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI), DBSI MRI | Washington University School of Medicine, National Cancer Institute (NCI) | Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas | 12/32 | 12/32 | | |
| Zhang, Qi |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT03750669: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 3 | 324 | RoW | AG regimen, Nab-paclitaxel and Gemcitabine, mFolfirinox, Folic acid, 5- fluorouracil, irinotecan and oxaliplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy | 04/24 | 04/26 | | |
| Terminated | 2 | 3 | RoW | osimertinib mesylate tablets and anlotinib hydrochloride capsules, TAGRISSO and FOCUS V | First Affiliated Hospital of Zhejiang University | Non Small Cell Lung Cancer | 12/22 | 02/23 | | |
NCT03662412: Study of Sirolimus in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Sirolimus, Rapamycin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Cancer | 06/23 | 06/23 | | |
NCT05224960: Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) |
|
|
| Recruiting | 2 | 140 | RoW | UC-MSCs, Placebo(solution without UC-MSCs) | Beijing 302 Hospital, Chinese PLA General Hospital, Shanghai Changzheng Hospital, LanZhou University, Jin Yin-tan Hospital, Hainan Hospital of Chinese PLA General Hospital, Vcanbio Cell and Gene Engineering Corp., Ltd., Third Affiliated Hospital, Sun Yat-Sen University, Xinjiang Kashi Area Number 1 Hospital | Decompensated Cirrhosis | 06/25 | 06/27 | | |
NCT03633773: Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 1/2 | 9 | RoW | MUC-1 CART cell immunotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intrahepatic Cholangiocarcinoma | 08/23 | 12/24 | | |
NCT03633747: Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma |
|
|
| Recruiting | 1/2 | 25 | RoW | Propranolol Hydrochloride | Second Affiliated Hospital, School of Medicine, Zhejiang University | Hemangioma Liver | 08/23 | 12/24 | | |
NCT03633734: Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1/2 | 49 | RoW | Sequential Treatment, Sequential Treatment With AG and Modified Folfirinox | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect | 08/23 | 12/24 | | |
NCT04533724: Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia |
|
|
| Not yet recruiting | 1 | 6 | NA | Amisulpride | Shanghai Mental Health Center | Negative Symptom, Schizophrenia, Amisulpride, Gut Microbiomes | 09/22 | 09/22 | | |
NCT06461624: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 15 | RoW | anti-GPC3 CAR-T, CBG166 CAR-T | Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Advanced Hepatocellular Carcinoma | 07/27 | 10/27 | | |
NCT06026605: A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 44 | RoW | WTX212A | Zhejiang University | Unresectable or Metastatic Advanced Solid Tumors | 08/26 | 08/26 | | |
| Recruiting | N/A | 200 | RoW | coronary revascularization | Shanghai East Hospital | Multivessel Coronary Artery Disease | 12/21 | 12/23 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
| Recruiting | N/A | 30 | Europe, US, RoW | | Sunnaas Rehabilitation Hospital, Oslo Metropolitan University, University of Oslo, Karolinska Institutet | Pediatric ALL, Spinal Cord Injuries | 12/22 | 12/24 | | |
NCT05475756: Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis |
|
|
| Recruiting | N/A | 264 | RoW | Intrauterine Biological Barrier, Intrauterine Adhesion Barrier Gel | Beijing Tiantan Hospital, Zhangzhou Municipal Hospital of Fujian Province, Guangzhou First People's Hospital, Tang-Du Hospital, Suzhou Municipal Hospital, Anhui Provincial Hospital | Intrauterine Adhesion | 05/24 | 05/25 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT05433935: Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas |
|
|
| Recruiting | N/A | 5000 | RoW | Observation | Zhejiang University, The Second Hospital of Hebei Medical University, Second Affiliated Hospital of Nanchang University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Huizhou Municipal Central Hospital, Shengzhou People's Hospital | Intraductal Papillary Mucinous Neoplasm | 06/32 | 12/33 | | |
| Zhao, Hui |
NCT06368882: Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT） |
|
|
| Recruiting | 4 | 1500 | RoW | Peg-Interferon α, nucleo(s)tide analogue | First Affiliated Hospital of Wenzhou Medical University | Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b | 12/28 | 12/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR |
|
|
| Recruiting | 1/2 | 160 | RoW | YK-029A | Suzhou Puhe Pharmaceutical Technology Co., LTD | Treatment, Treatment Side Effects | 12/23 | 05/24 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT03814447: The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer |
|
|
| Recruiting | 1 | 10 | RoW | anti- MESO CAR-T cells, Fludarabine, FA, Cyclophosphamide, CTX | Shanghai 6th People's Hospital, Hrain Biotechnology Co., Ltd. | Ovarian Cancer | 01/23 | 01/23 | | |
NCT05659927: Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 34 | RoW | MG-ZG122 Humanized Monoclonal Antibody Injection, MG-ZG122, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 01/24 | 03/24 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
NCT04948502: SaExten Vena Cava Filter System in Prevention of Pulmonary Embolism |
|
|
| Completed | N/A | 192 | RoW | SaExten vena cava filter system, SaExten VCF system, Denali inferior vena cava filter, Denali IVCF | ShenZhen KYD Biomedical Technology Co., Ltd. | Pulmonary Embolism | 01/22 | 09/22 | | |
NCT04568291: CTC in Lung Caner Patients With Bone Metastases |
|
|
| Recruiting | N/A | 160 | RoW | model treatment, routine treatment | Shanghai 6th People's Hospital | Lung Cancer, Bone Metastases, Single Cell Sequencing Technology | 03/22 | 12/22 | | |
NCT03876392: Detection of Bone Marrow Metastases With Magnetic Resonance Imaging |
|
|
| Recruiting | N/A | 50 | RoW | magnetic resonance imaging | Shanghai 6th People's Hospital | Bone Marrow Metastases, Magnetic Resonance Imaging | 12/22 | 12/22 | | |
PROSTA, NCT05356767: The Study of Percutaneous Mechanical Thrombectomy Treating Acute Deep Vein Thrombosis of Lower Extremities |
|
|
| Recruiting | N/A | 600 | RoW | Pharmacomechanical thrombolysis | Chengdu University of Traditional Chinese Medicine | Pharmacomechanical Thrombolysis, Deep Vein Thrombosis | 04/24 | 04/26 | | |
SURF, NCT06539689: A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries |
|
|
| Recruiting | N/A | 240 | RoW | Sperstent® peripheral spot stent system, Everflex® self-expanding peripheral stent system | FrontAce Scientific Co., Ltd | Peripheral Arterial Disease, Stenosis, Dissection | 12/26 | 12/26 | | |
NCT06775808: Total Infectome Characterization of Eye Infections |
|
|
| Recruiting | N/A | 200 | RoW | | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Eye Infections, Diagnosis | 10/26 | 12/26 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Liu, Bo |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults |
|
|
| Active, not recruiting | 3 | 3038 | Europe, Canada, Japan, US, RoW | HZ/su vaccine | GlaxoSmithKline | Herpes Zoster | 08/27 | 08/27 | | |
| Not yet recruiting | 3 | 8862 | RoW | Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo | Wuhan Union Hospital, China | Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine | 03/28 | 08/28 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT04835324: Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study |
|
|
| Active, not recruiting | N/A | 650 | RoW | | Chinese Academy of Medical Sciences, Beijing Hospital, Jiangsu Cancer Institute & Hospital, The Affiliated Hospital of Qingdao University, Shanxi Province Cancer Hospital, Affiliated Hospital of Hebei University, Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Zhengzhou University, Hebei Medical University Fourth Hospital, First Hospital of China Medical University | Advanced Colorectal Cancer | 02/22 | 10/22 | | |
| Completed | N/A | 60 | RoW | Avocado extract, Placebo | University of Adelaide, Isagenix International LLC, Commonwealth Scientific and Industrial Research Organisation, Australia, Prolongevity Technologies | Obesity | 08/22 | 08/22 | | |
| Recruiting | N/A | 701 | RoW | Liver-cancer early detection test | The First Hospital of Jilin University, Guangzhou Burning Rock Dx Co., Ltd. | Liver Cancer | 12/23 | 12/23 | | |
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA |
|
|
| Recruiting | N/A | 492 | RoW | | LI YAN | T2DM | 12/25 | 07/26 | | |
| Guoying, Wang |
NCT04564313: Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation |
|
|
| Recruiting | 1 | 20 | RoW | Camrelizumab treatment | Third Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma, Liver Transplantation | 09/22 | 07/23 | | |
| Yi, Huimin |
LTeCRRT, NCT04317222: Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE |
|
|
| Not yet recruiting | N/A | 250 | NA | eCRRT | Third Affiliated Hospital, Sun Yat-Sen University | Acute-On-Chronic Liver Failure, Hepatic Encephalopathy | 05/22 | 08/22 | | |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| Lv, Haijin |
NCT05707520: Long-term Benefit of MPA in Liver Transplantation |
|
|
| Recruiting | N/A | 500 | RoW | enteric-coated mycophenolate (MPAs), None MPA | Third Affiliated Hospital, Sun Yat-Sen University, Shulan (Hangzhou) Hospital, RenJi Hospital, The First Affiliated Hospital of Zhengzhou University, Beijing YouAn Hospital, Huashan Hospital, The Third Xiangya Hospital of Central South University, West China Hospital, Hebei Medical University Third Hospital, People's Hospital of Guangxi, Beijing Friendship Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Liver Transplant Rejection, Immunosuppressant Adverse Reaction | 06/23 | 09/23 | | |
| chen, huiqin |
| Recruiting | 2/3 | 43 | RoW | Cladribine, cladribine injection, G-CSF, granulocyte, Cytarabine, Ara-C, Idarubicin, Idamycin, IDA, Mitoxantrone, MIT, Sorafenib, sorafinib, Nexavar, sorafenib tosylate | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Maternal and Child Health Hospital of Foshan, The First Affiliated Hospital of Guangzhou Medical University, Second Xiangya Hospital of Central South University, Jiangxi Province Children's Hospital, Southern Medical University, China, The First Affiliated Hospital of Nanchang University, Guangzhou First People's Hospital, First Affiliated Hospital of Shantou University Medical College | Leukemia, Monocytic, Acute, Pediatric AML | 03/26 | 03/26 | | |
| Li, Siqi |
NCT05803928: Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies |
|
|
| Recruiting | 1 | 70 | RoW | lenvatinib + anti-PD-1 antibodies, ablation | Hua Li | Hepatocellular Carcinoma | 11/24 | 04/25 | | |
| Zhang, Yingcai |
NCT05940610: The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure |
|
|
| Withdrawn | 1/2 | 20 | RoW | MSC-EVs | Third Affiliated Hospital, Sun Yat-Sen University | Acute-On-Chronic Liver Failure, Acute Liver Failure | 09/24 | 10/25 | | |
| Mo, Jian |
| Recruiting | N/A | 50 | RoW | Multifaceted Intervention | Third Affiliated Hospital, Sun Yat-Sen University, Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Longgang Orthopedics Hospital of Shenzhen, The First People's Hospital of Hefei, Dongguan Eighth People's Hospital, The Third People's Hospital of Longgang District Shenzhen | Fragility Fracture | 06/25 | 06/27 | | |
| Yu, Haoyuan |
NCT05803928: Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies |
|
|
| Recruiting | 1 | 70 | RoW | lenvatinib + anti-PD-1 antibodies, ablation | Hua Li | Hepatocellular Carcinoma | 11/24 | 04/25 | | |
